Post-Frontline Sequential Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Ancillary Observational Study of Post-Frontline Sequential Treatment of Adult Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients With Dasatinib and the Bispecific Monoclonal Antibody Blinatumomab
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Bari, Italy
- Recruiting
- Aou Consorziale Policlinico - Bari - Uo Ematologia Con Trapianto
-
Contact:
- Francesco Albano
- Phone Number: 080 5478031
- Email: francesco.albano@uniba.it
-
Bergamo, Italy
- Recruiting
- Asst Papa Giovanni Xxiii - Ospedale Di Bergamo - Sc Ematologia
-
Brescia, Italy
- Recruiting
- Asst Degli Spedali Civili Di Brescia - Uo Ematologia
-
Catania, Italy
- Recruiting
- CTC U.O di Ematologia con Trapianto di Midollo Osseo - Catania
-
Contact:
- Francesco Di Raimondo
- Phone Number: 3284782450
- Email: diraimon@unict.it
-
Firenze, Italy
- Recruiting
- AOU Careggi - Firenze - SOD Ematologia
-
Contact:
- Matteo Piccini
- Phone Number: 3480649138
- Email: matt.piccini@gmail.com
-
Lecce, Italy
- Recruiting
- Asl Lecce, Ospedale 'V. Fazzi' - Uo Ematologia
-
Mestre, Italy
- Recruiting
- Aulss 3 Serenissima, Ospedale Dell'Angelo - Mestre - Uo Ematologia
-
Milano, Italy
- Recruiting
- Fondazione Irccs Ca' Granda, Ospedale Maggiore Policlinico - Milano - Ematologia - Padiglione Marcora
-
Novara, Italy
- Recruiting
- Aou Maggiore Della Carita' Di Novara - Scdu Ematologia
-
Contact:
- Monia Lunghi
- Phone Number: 3382605628
- Email: monia.lunghi@med.unipmn.it
-
Orbassano, Italy
- Recruiting
- Aou San Luigi Gonzaga - Orbassano - Scdu Ematologia Generale E Oncoematologia
-
Contact:
- Giovanna Rege Cambrin
- Phone Number: 3282170617
- Email: giovanna.rege@libero.it
-
Pagàni, Italy
- Recruiting
- Asl Salerno, Presidio Ospedaliero Tortora Pagani - Ematologia
-
Contact:
- Catello Califano
- Phone Number: 3347098147
- Email: c.califano@aslsalerno.it
-
Parma, Italy
- Recruiting
- Aou Di Parma - Sc Ematologia E Centro Trapianti Midollo Osseo
-
Contact:
- Monica Crugnola
- Phone Number: 3464030767
- Email: mcrugnola@ao.pr.it
-
Perugia, Italy
- Recruiting
- AO di Perugia, Ospedale S. Maria della Misericordia - Ematologia E Trapianto Midollo Osseo
-
Roma, Italy
- Recruiting
- Università Degli Studi Di Roma "Sapienza" - Dipartimento Di Medicina Traslazionale E Di Precisione - U.O.C. Ematologia
-
Contact:
- Sabina Chiaretti
- Phone Number: 3331132942
- Email: chiaretti@bce.uniroma1.it
-
Roma, Italy
- Recruiting
- Aou Policlinico Tor Vergata - Roma - Uoc Trapianto Cellule Staminali
-
Rome, Italy
- Not yet recruiting
- Dipartimento di Biotecnologie Cellulari ed Ematologia "Sapienza" Università degli Studi di Roma
-
Verona, Italy
- Recruiting
- Aou Integrata Di Verona, Policlinico G.B. Rossi - Uoc Ematologia
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Study LAL2217 Informed Consent signature.
- Patients enrolled in the GIMEMA LAL2116 protocol and who have completed the 12 months follow-up
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
All patients
All eligible patients enrolled in the GIMEMA LAL2116 study who have completed 12 months follow-up will be included in this group.
|
Patients treated frontline with the sequential administration of dasatinib and the bispecific monoclonal antibody blinatumomab according to the protocol LAL2116
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of patients alive
Time Frame: At five years since study entry
|
At five years since study entry
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of therapeutic choices taken after dasatinib and blinatumomab (induction/consolidation) according to individual medical decisions and clinical practice.
Time Frame: At five years from study entry
|
Characteristics of these choices
|
At five years from study entry
|
|
Number of days in complete molecular remission.
Time Frame: At five years from study entry
|
Duration of remission
|
At five years from study entry
|
|
Number of patients in disease-free survival
Time Frame: At five years from study entry
|
At five years from study entry
|
|
|
Number of adverse events
Time Frame: At five years from study entry
|
Long-term safety profile
|
At five years from study entry
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Roberto Foà, Prof., Dipartimento di Biotecnologie Cellulari ed Ematologia "Sapienza" Università degli Studi di Roma
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Chromosome Aberrations
- Translocation, Genetic
- Leukemia
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Leukemia, Lymphoid
- Philadelphia Chromosome
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Blinatumomab
- Dasatinib
Other Study ID Numbers
Other Study ID Numbers
- LAL2217
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.